MX2021014228A - Formas cristalinas de sal de n-(4-(4 (ciclopropilmetil)piperazin 1- carbonil)fenil)quinolin-8-sulfonamida. - Google Patents
Formas cristalinas de sal de n-(4-(4 (ciclopropilmetil)piperazin 1- carbonil)fenil)quinolin-8-sulfonamida.Info
- Publication number
- MX2021014228A MX2021014228A MX2021014228A MX2021014228A MX2021014228A MX 2021014228 A MX2021014228 A MX 2021014228A MX 2021014228 A MX2021014228 A MX 2021014228A MX 2021014228 A MX2021014228 A MX 2021014228A MX 2021014228 A MX2021014228 A MX 2021014228A
- Authority
- MX
- Mexico
- Prior art keywords
- salt forms
- crystalline salt
- cyclopropylmethyl
- sulfonamide
- quinoline
- Prior art date
Links
- 150000003839 salts Chemical group 0.000 title abstract 3
- XAYGBKHKBBXDAK-UHFFFAOYSA-N n-[4-[4-(cyclopropylmethyl)piperazine-1-carbonyl]phenyl]quinoline-8-sulfonamide Chemical compound C=1C=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=CC=1C(=O)N(CC1)CCN1CC1CC1 XAYGBKHKBBXDAK-UHFFFAOYSA-N 0.000 title 1
- 108020005115 Pyruvate Kinase Proteins 0.000 abstract 1
- 102000013009 Pyruvate Kinase Human genes 0.000 abstract 1
- 108700014121 Pyruvate Kinase Deficiency of Red Cells Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 e.g. Proteins 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente descripción se proporcionan varias formas cristalinas de sal del compuesto (I) representadas por la siguiente fórmula estructural: (ver formula) (I). También se proporcionan composiciones farmacéuticas que comprenden las formas cristalinas de sales, métodos para su fabricación y usos de estas para tratar afecciones asociadas con la piruvato quinasa tal como, por ejemplo, la deficiencia de piruvato quinasa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962851344P | 2019-05-22 | 2019-05-22 | |
| PCT/US2020/033992 WO2020237047A1 (en) | 2019-05-22 | 2020-05-21 | Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014228A true MX2021014228A (es) | 2022-02-21 |
Family
ID=71016713
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014228A MX2021014228A (es) | 2019-05-22 | 2020-05-21 | Formas cristalinas de sal de n-(4-(4 (ciclopropilmetil)piperazin 1- carbonil)fenil)quinolin-8-sulfonamida. |
| MX2024009648A MX2024009648A (es) | 2019-05-22 | 2021-11-19 | Formas cristalinas de sal de n-(4-(4-(ciclopropilmetil)piperazin-1 -carbonil)fenil)quinolin-8-sulfonamida. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009648A MX2024009648A (es) | 2019-05-22 | 2021-11-19 | Formas cristalinas de sal de n-(4-(4-(ciclopropilmetil)piperazin-1 -carbonil)fenil)quinolin-8-sulfonamida. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230192618A1 (es) |
| EP (1) | EP3972957A1 (es) |
| JP (1) | JP2022533227A (es) |
| CN (2) | CN114026071B (es) |
| AU (1) | AU2020280045A1 (es) |
| CA (1) | CA3145138A1 (es) |
| IL (1) | IL288158A (es) |
| MX (2) | MX2021014228A (es) |
| WO (1) | WO2020237047A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202329935A (zh) | 2021-11-16 | 2023-08-01 | 美商阿吉歐斯製藥公司 | 用於治療ｍｄｓ相關聯之貧血及其他病況之化合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI598337B (zh) | 2009-06-29 | 2017-09-11 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| MD3307271T2 (ro) | 2015-06-11 | 2024-01-31 | Agios Pharmaceuticals Inc | Metode de utilizare a activatorilor de piruvat kinază |
| TWI808108B (zh) * | 2017-11-22 | 2023-07-11 | 美商阿吉歐斯製藥公司 | N-(4-(4-(環丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺醯胺之結晶型 |
-
2020
- 2020-05-21 AU AU2020280045A patent/AU2020280045A1/en active Pending
- 2020-05-21 US US17/612,554 patent/US20230192618A1/en active Pending
- 2020-05-21 JP JP2021569059A patent/JP2022533227A/ja active Pending
- 2020-05-21 EP EP20731357.8A patent/EP3972957A1/en active Pending
- 2020-05-21 WO PCT/US2020/033992 patent/WO2020237047A1/en unknown
- 2020-05-21 CA CA3145138A patent/CA3145138A1/en active Pending
- 2020-05-21 MX MX2021014228A patent/MX2021014228A/es unknown
- 2020-05-21 CN CN202080045139.1A patent/CN114026071B/zh active Active
- 2020-05-21 CN CN202410205860.2A patent/CN118206485A/zh active Pending
-
2021
- 2021-11-16 IL IL288158A patent/IL288158A/en unknown
- 2021-11-19 MX MX2024009648A patent/MX2024009648A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020237047A1 (en) | 2020-11-26 |
| AU2020280045A1 (en) | 2021-12-23 |
| US20230192618A1 (en) | 2023-06-22 |
| CN114026071B (zh) | 2024-03-01 |
| CN114026071A (zh) | 2022-02-08 |
| CA3145138A1 (en) | 2020-11-26 |
| EP3972957A1 (en) | 2022-03-30 |
| JP2022533227A (ja) | 2022-07-21 |
| MX2024009648A (es) | 2024-08-19 |
| IL288158A (en) | 2022-01-01 |
| CN118206485A (zh) | 2024-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009998A (es) | Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1- carbonil)fenil)quinolin-8-sulfonamida. | |
| TN2019000192A1 (en) | Pyrazole derivatives as malt1 inhibitors | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX2021014350A (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos. | |
| TW200745066A (en) | Novel PTP1B inhibitors | |
| MX2013012776A (es) | Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina. | |
| MX2020009234A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos. | |
| WO2019035863A8 (en) | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | |
| MX2017004600A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| TN2017000075A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| EA201792433A1 (ru) | Производные 2-(фенилокси- или фенилтио)пиримидина в качестве гербицидов | |
| WO2014031438A3 (en) | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS | |
| MX2020013699A (es) | Derivados de pirazol como inhibidores de malt1. | |
| EA201990279A1 (ru) | Гербицидные композиции, содержащие фенилпиримидины | |
| MX2020013899A (es) | Derivados de pirazol como inhibidores de malt1. | |
| WO2021011713A8 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| MX2021006951A (es) | Formas cristalinas y formas de sal de un inhibidor de cinasa. | |
| MX2020002449A (es) | Nuevos compuestos heterociclicos fungicidas. | |
| MX2021012105A (es) | Compuestos de pirrol. | |
| WO2018039077A8 (en) | Therapeutic compounds | |
| GEP20247655B (en) | Crystalline salt forms of kinase inhibitor | |
| CR20220004A (es) | Nuevos compuestos heterocíclicos | |
| MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
| MX2021014680A (es) | Derivado de benzotriazol. | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof |